Delaloge S, Dureau S, D'Hondt V, Desmoulins I, et al. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. Eur J Cancer 2022 Mar 22. pii: S0959-8049(22)00035.
PMID: 35337692